425 related articles for article (PubMed ID: 18498241)
1. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
[TBL] [Abstract][Full Text] [Related]
2. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
5. Parallel evolutions of the growth rate of newly diagnosed HIV cases and the proportion of potentially infective patients in Cayenne French Guiana: should HAART be used to curb the epidemic?
Nacher M; Vantilcke V; Huber F; El Guedj M; Vaz T; Magnien C; Djossou F; Mahamat A; Dabis F; Couppié P
Public Health; 2009 Aug; 123(8):573-4. PubMed ID: 19692100
[No Abstract] [Full Text] [Related]
6. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?
Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ
Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234
[No Abstract] [Full Text] [Related]
7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
8. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
[TBL] [Abstract][Full Text] [Related]
9. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy.
Bezemer D; de Wolf F; Boerlijst MC; van Sighem A; Hollingsworth TD; Prins M; Geskus RB; Gras L; Coutinho RA; Fraser C
AIDS; 2008 May; 22(9):1071-7. PubMed ID: 18520351
[TBL] [Abstract][Full Text] [Related]
10. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India.
Kumarasamy N; Solomon S; Chaguturu SK; Cecelia AJ; Vallabhaneni S; Flanigan TP; Mayer KH
Clin Infect Dis; 2005 Nov; 41(10):1525-8. PubMed ID: 16231268
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of antiretroviral multiclass resistance.
Lima VD; Harrigan PR; Sénécal M; Yip B; Druyts E; Hogg RS; Montaner JS
Am J Epidemiol; 2010 Aug; 172(4):460-8. PubMed ID: 20667931
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
14. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
15. CD4 cell count-guided treatment interruption: be smart and wait for more evidence.
Arduino R
Clin Infect Dis; 2005 Mar; 40(5):735-7. PubMed ID: 15714421
[No Abstract] [Full Text] [Related]
16. Dynamics and evolution of HIV-1 during structured treatment interruptions.
Frost SD
AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
Lucas GM
J Antimicrob Chemother; 2005 Apr; 55(4):413-6. PubMed ID: 15722389
[TBL] [Abstract][Full Text] [Related]
18. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
20. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
